Pathological and Clinical Response of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Paclitaxel as Neoadjuvant Treatment in Patients with Operable Breast Cancer
2005
This phase II study investigated the efficacy and tolerability of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel (VEP protocol) in women with stage II/III operable breast cancer. Patients (n = 50) were treated with six cycles of VEP according to the following schedule: vinorelbine (Navelbine ® ; Pierre Fabre, Boulogne, France; http://www.pierre-fabre.com) 20 mg/m 2 , epirubicin (Farmorubicin ® ; Pharmacia, New
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
21
References
11
Citations
NaN
KQI